Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you consider using trastuzumab deruxtecan in HER2-low expressing NSCLC based on data from breast cancer?
Related Questions
How do you decide between Neoadjuvant (Checkmate 816) and Peri-adjuvant (Keynote 671) chemoimmunotherapy for early stage NSCLC?
How does the presence of both T790M and L858R EGFR mutations impact the prognosis and management of a patient with previously untreated locally advanced adenocarcinoma of the lung?
Would you offer adjuvant pembrolizumab to a stage II-III adenocarcinoma of the lung who had a complete pathologic response to 4 cycles of cisplatin/pemetrexed/pembro (KN-671)?
Would you ever consider repeating chemoradiation for patients with locally recurrent small cell lung cancer after prior chemoradiation for LS-SCLC?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
How would you manage a patient with radiation pneumonitis who remains symptomatic on steroids?
How would you approach a patient with limited stage SCLC who progressed immediately after completing chemoradiation with brain metastasis?
How would you manage a left sided triple negative breast cancer with a concurrent left sided locally advanced non-small cell lung cancer?
How do the results of TROPION-Lung01 Phase III trial change your practice in the management of locally advanced or metastatic NSCLC?
In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with Osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?
